Global Point-of-Care or Rapid Testing Market Size By Type (Blood Glucose Testing, Infectious Diseases Testing), By Application (Clinics, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

The Global Point-of-Care (POC) or Rapid Testing Market was valued at USD 38.4 billion in 2023 and is expected to reach USD 78.2 billion by 2031, growing at a CAGR of 9.3% during the forecast period from 2023 to 2031. The rapid testing market has seen significant momentum, fueled by rising demand for immediate diagnostic results, particularly in infectious disease detection, chronic condition monitoring, and emergency care. The integration of advanced biosensor technologies, microfluidics, and connectivity-enabled devices continues to transform the diagnostic landscape, shifting from centralized laboratories to decentralized, patient-centric care models.

Drivers:

1. Rising Prevalence of Chronic and Infectious Diseases

The increasing global burden of diseases such as diabetes, cardiovascular conditions, and respiratory infections is a key driver. POC testing enables early diagnosis, reducing hospitalizations and enabling effective disease management.

2. Technological Advancements in POC Devices

Innovations in molecular diagnostics, miniaturization, and integration of smartphone connectivity are enhancing accuracy, usability, and real-time data sharing, making POC testing more accessible and reliable.

3. Growing Demand for Home Healthcare and Remote Monitoring

With the aging population and the push towards decentralized healthcare, rapid tests are increasingly used at home for monitoring chronic diseases, post-surgical recovery, and wellness tracking.

Restraints:

1. Regulatory and Quality Concerns

Inconsistent regulatory frameworks and the need for stringent quality control in POC testing devices pose challenges for manufacturers, particularly in emerging economies.

2. Limited Sensitivity in Some Applications

While convenient, certain POC tests may have lower sensitivity or specificity compared to centralized lab diagnostics, potentially leading to false results in critical care scenarios.

Opportunity:

1. Expansion in Emerging Markets

Countries in Asia-Pacific, Latin America, and Africa are rapidly improving healthcare access and investing in mobile diagnostic solutions. These regions offer untapped potential for POC adoption in both rural and urban settings.

2. Integration with Digital Health Platforms

POC testing is increasingly integrated with electronic health records (EHRs) and telemedicine platforms, creating opportunities for real-time decision-making and personalized healthcare delivery.

Market by System Type Insights:

The Lateral Flow Assays segment held the largest market share in 2023 due to its widespread application in infectious disease testing, pregnancy detection, and COVID-19 diagnostics. However, the Molecular Diagnostics POC segment is projected to witness the fastest growth rate, driven by innovations in nucleic acid testing and demand for high-precision tools in decentralized settings.

Market by End-use Insights:

In 2023, the Hospitals & Clinics segment accounted for the largest share, supported by the need for rapid triage and immediate decision-making. The Homecare Settings segment is expected to grow robustly due to increasing preference for at-home diagnostics, especially among the elderly population and individuals with chronic illnesses.

Market by Regional Insights:

North America dominated the global market in 2023, driven by technological leadership, strong healthcare infrastructure, and supportive reimbursement policies. Asia-Pacific is forecasted to be the fastest-growing region, fueled by healthcare digitization, government investments, and rising demand for affordable diagnostic solutions.

Competitive Scenario:

Key players in the Global Point-of-Care or Rapid Testing Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, bioMérieux SA, QuidelOrtho Corporation, BD (Becton, Dickinson and Company), Chembio Diagnostics, Sekisui Diagnostics, and Thermo Fisher Scientific. These companies are leveraging AI, mobile integration, and cloud-based platforms to enhance product performance and accessibility.

Scope of Work – Global Point-of-Care or Rapid Testing Market

Report Metric Details

Market Size (2023) USD 38.4 billion

Projected Market Size (2031) USD 78.2 billion

CAGR (2023–2031) 9.3%

Market Segments System Type (Lateral Flow Assays, Molecular Diagnostics, Others); End-use (Hospitals & Clinics, Homecare Settings, Diagnostic Centers)

Growth Drivers Rising disease burden, tech innovation, decentralized healthcare

Opportunities Emerging markets, digital health integration

Key Market Developments:

June 2023: Abbott launched an advanced COVID-19 and influenza combo rapid test for over-the-counter use with mobile app integration.

March 2024: Roche introduced a next-gen molecular POC testing device with AI-enhanced analytics for infectious disease detection.

January 2025: Siemens Healthineers announced a collaboration with telehealth providers to link POC testing directly with remote diagnostics platforms.

FAQs:

1. What is the current market size of the Global Point-of-Care or Rapid Testing Market?

The market size was va